News & Updates
Showing Multidisciplinary articles
Showing

Universal HCV screening in pregnancy: A step toward reducing transmission?
Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.

Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
In patients with gout and concurrent chronic kidney disease (CKD), the risk of mortality does not seem to increase with initiation of allopurinol, achieving target serum urate (SU) level with allopurinol, or treatment dose escalation, a study has shown.

Treatment coverage for major depressive disorder still wanting in poorer countries
Treatment coverage for major depressive disorder (MDD) remains low across the globe, especially in low- and lower middle-income countries, a study has found. However, many patients still fail to receive adequate care consistent with practice guidelines even in high-income countries.

NOACs better than warfarin in diabetic patients with atrial fibrillation
Treatment with nonvitamin K antagonist oral anticoagulants (NOACs) results in lower risks of diabetes complications and mortality compared with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus (DM), suggest a study.

First data from Vaccine Allergy Safety clinics reaffirm COVID-19 vaccine safety
First data from Vaccine Allergy Safety (VAS) clinics in Hong Kong show that a majority of high-risk patients can receive coronavirus disease 2019 (COVID-19) vaccination safely, with no immediate allergic reactions.

High-dose ipilimumab augments nivolumab benefit for TCC
In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Corticosteroid-remdesivir combo suppresses secondary infections in severe COVID-19
The combination of corticosteroid (CS) therapy with remdesivir (RDV) has noninferior survival outcomes relative to CS monotherapy in patients hospitalized with the coronavirus disease 2019 (COVID-19), reports a recent study.


